top of page

News of Note - February 22, 2023

BULL BEAR BRES|NAHAN

Wednesday, February 22, 2023

14:32:46



Riders on the storm

Riders on the storm

Into this house, we're born

Into this world, we're thrown

Like a dog without a bone

An actor out on loan

Riders on the storm



Like a hitchhiker, into your vehicle, you ought to be mindful of what you let into your portfolio and investment strategy.. Don’t just pick things up along the highway unless you’re ready to deal with ‘a rider on the storm’.


😊


Br. -john



 


*PRESS RELEASES*



PFE

Pfizer


Elranatamab Receives FDA and EMA Filing Acceptance

  • Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma

  • FDA has granted Priority Review

  • FDA’s decision on the application is expected in 2023

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.



MRK

Merck


Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

  • Islatravir and other HIV data presented at CROI 2023

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.



CERE

Cerevel Therapeutics


Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates


Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.



AZN LN | AZN SS | AZN

AstraZeneca


Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers

  • Approvals based on significant survival benefits in HIMALAYA and POSEIDON Phase III trials

Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia

  • Tablet formulation can be co-administered with gastric acid-reducing agents

  • allowing greater patient and physician choice

  • Approval based on ELEVATE-PLUS trials which showed

  • bioequivalence and consistent dosing vs. current capsule

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.



STLAM IM | STLAP FP | STLA

Stellantis


Release

https://www.stellantis.com/en/news/press-releases/2023/february/full-year-2022-results


Presentation

https://www.stellantis.com/content/dam/stellantis-corporate/investors/events-and-presentations/presentations/Stellantis_FY_22_Results_Presentation.pdf


Webcast

https://channel.royalcast.com/stellantis-en/#!/stellantis-en/20230222_1


Stellantis N.V. engages in the design, engineering, manufacturing, distribution, and sale of automobiles and light commercial vehicles, engines, transmission systems, metallurgical products, and production systems worldwide.



SALM NO

SalMar


Remain on the sidelines due to the Norwegian governments tax shenanigans..


Release

https://www.salmar.no/en/feedposts/announcements/?dh=aHR0cHM6Ly9yc3MuZ2xvYmVuZXdzd2lyZS5jb20vSGV4TUxJdGVtL0NvbnRlbnQvRnVsbFRleHQvQXR0YWNobWVudHMvQWxsL0lkZW50aWZpZXIvMjYxMjgxMy9sYW5ndWFnZS9lbg==


Presentation

https://ml-eu.globenewswire.com/Resource/Download/5fdb5934-9062-4f30-bfb1-51ec68bc6d48


Report

https://ml-eu.globenewswire.com/Resource/Download/ce841deb-32fc-459b-8972-a0d7a78f3e82



Webcast

https://events.webcast.no/salmar-asa/quarterly-reports/salmar-asa-results-4th-quarter-2022


SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, the United States, Canada, Norway, rest of Europe, and internationally.



UCB BB | UCBJY

UCB


Sales are important, yes, though the real story here is ‘Bimekizumab’ and the pipeline..


Release

https://www.ucb.com/stories-media/Press-Releases/article/UCB-managed-2022-headwinds-and-is-ready-for-2023-launches


Report

https://www.ucb.com/sites/default/files/2023-02/2022_Full-Year_Management_Report.pdf


Webcast

https://forms.office.com/e/mxr1a8QsaN


UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. -CapIQ



ROIV

Roivant Sciences


Announces Change to its Board of Directors

  • Founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.



BINV SS

BioInvent


Release/ Report

https://storage.mfn.se/38536733-229b-4c87-a402-376fa4d6b171/bioinvent-q4-2022-eng.pdf


BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally.



 


*ARTICLES, ETC.*


Bloomberg


McKinsey Plans to Eliminate About 2,000 Jobs in One of Its Biggest Rounds of Cuts

  • Firm that advises on headcount reductions takes aim at its own

  • One of management consultant’s biggest rounds of job cuts ever


Dutch Premier Pokes China While Praising ‘Century of America’

  • “The 21st century will be the century of democracy and thus the century of America.”



Financial Times


Morgan Stanley: Welcome to the ‘death zone’

  • Does a double-black-diamond run await?

  • Bottom line, investors are not bearish any longer, and this is just another reason to be wary of the set-up going into what is likely to be another weak earnings season.



Stat


Dutch group sues AbbVie for human rights violations stemming from Humira pricing

  • The latest lawsuit, however, goes beyond the usual discussion of excessive pricing and abusing a dominant market position by arguing that AbbVie had a “social duty of care” to ensure that its practices did not impede access to legally insured basic care.



Evaluate


Novo sows the seeds for a new heart failure approach

  • The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.



Ars Technica


SCOTUS “confused” after hearing arguments for weakening Section 230 immunity

  • SCOTUS sways Google’s way, says eroding Section 230 could crash digital economy

bottom of page